Aurora Kinase A as a Central Regulator of Trained Immunity through SAM Metabolism

Study Background and Research Question

Trained immunity refers to the capacity of innate immune cells, such as monocytes and macrophages, to adopt a memory-like phenotype after initial stimulation. Unlike adaptive immune memory, trained immunity is driven by epigenetic and metabolic reprogramming, enabling a rapid and potentiated response upon secondary challenge. This phenomenon can be induced by microbial components like β-glucan and is characterized by changes in chromatin accessibility—specifically, enhanced histone methylation at gene loci encoding inflammatory mediators. However, the upstream regulatory mechanisms that couple cellular metabolism to this chromatin reprogramming remain incompletely understood, particularly the role of S-adenosylmethionine (SAM), a critical methyl donor for histone modifications.

Aurora kinase A (AurA), a serine/threonine kinase best known for its functions in mitosis and frequently overexpressed in various cancers, has recently emerged as an intersecting node between cell cycle regulation and cancer immunobiology. The key question addressed by Li et al. (eLife 2025;14:RP104138) is whether and how AurA orchestrates trained immunity by mediating endogenous SAM metabolism and epigenetic remodeling in innate immune cells.

Key Innovation from the Reference Study

The study by Li et al. introduces a novel mechanistic link between AurA activity and the maintenance of trained immunity, mediated by endogenous SAM homeostasis. Specifically, the authors demonstrate that inhibition of AurA disrupts β-glucan-induced trained immunity, not only by limiting chromatin accessibility at key inflammatory loci but also by reducing intracellular SAM levels through regulation of the mTOR–FOXO3–GNMT axis. This represents a significant advance in understanding how metabolic and epigenetic layers are integrated in the functional programming of innate immunity.

Methods and Experimental Design Insights

• Pharmacological and Genetic Inhibition of AurA: The authors utilize both small-molecule inhibitors of AurA and genetic knockdown approaches to interrogate the kinase's role in trained immunity.
• Trained Immunity Induction: Primary mouse macrophages and in vivo mouse models were exposed to β-glucan to induce a trained immunity phenotype, followed by secondary stimulation to assess functional responses.
• Epigenomic and Transcriptomic Profiling: ATAC-seq and RNA-seq were performed to characterize changes in chromatin accessibility and gene expression profiles upon AurA modulation.
• Metabolomics: LC-MS-based metabolomic analysis quantified intracellular SAM and related metabolites to delineate metabolic consequences of AurA inhibition.
• Chromatin Immunoprecipitation (ChIP): ChIP-qPCR for H3K4me3 and H3K36me3 at Il6 and Tnf loci assessed the impact of SAM changes on histone methylation marks crucial for inflammatory gene induction.
• Tumor Growth Assays: The effect of AurA inhibition on the anti-tumor activity of β-glucan-induced trained immunity was evaluated in syngeneic mouse tumor models.

Protocol Parameters

• β-glucan priming: Mouse macrophages pre-treated with β-glucan (typically 20 μg/mL) for 24 hours to induce trained immunity phenotype before secondary challenge.
• AurA inhibition: Administration of AurA inhibitors at concentrations validated for kinase selectivity and minimal cytotoxicity in cultured cells (e.g., 100 nM for in vitro studies).
• Metabolomic sampling: Cells harvested at 24–48 hours post-inhibitor treatment for LC-MS analysis of SAM levels.
• ChIP-qPCR: Chromatin prepared from trained and untrained cells 3–6 hours after secondary stimulation for histone methylation analysis.
• In vivo tumor assays: Mice treated orally with β-glucan and/or AurA inhibitor daily; tumor volume measured every 2–3 days for up to 21 days.

Core Findings and Why They Matter

The authors provide direct evidence that AurA is essential for the maintenance of trained immunity. Inhibition of AurA, either pharmacologically or genetically, abrogates the heightened inflammatory response typically observed in β-glucan-trained macrophages. This effect is traced to a reduction in chromatin accessibility at genes involved in key inflammatory pathways (JAK-STAT, TNF, NF-κB), as revealed by ATAC-seq and RNA-seq.

Mechanistically, AurA inhibition leads to increased nuclear localization of FOXO3 and upregulation of glycine N-methyltransferase (GNMT), which accelerates SAM consumption. As a result, intracellular SAM is depleted, leading to decreased H3K4me3 and H3K36me3 at promoters of Il6 and Tnf, two critical cytokine genes. This methylation deficit impairs the transcriptional priming required for trained immune responses.

Importantly, in vivo experiments demonstrate that AurA inhibition negates the tumor growth inhibition normally achieved by β-glucan-induced trained immunity, underscoring the functional relevance of this pathway to anti-tumor immunity. These findings position AurA as a key metabolic-epigenetic integrator in cancer biology and immune regulation, with implications for both fundamental research and therapeutic development (Li et al., eLife 2025).

Comparison with Existing Internal Articles

Several recent articles in the cancer biology field have explored the translational significance of targeting Aurora A kinase, especially with selective inhibitors such as MLN8237 (Alisertib). For instance, the article "MLN8237 (Alisertib) and the Aurora Kinase Frontier" examines the mechanistic rationale for Aurora A inhibition in oncogenesis and tumor progression. It highlights how MLN8237’s selectivity allows for robust apoptosis induction in tumor cells and the suppression of tumor growth in animal models, which is aligned with the reference study’s focus on the interplay between kinase activity and cellular phenotype.

Another resource, "MLN8237 (Alisertib): Protocol-Driven Workflows in Cancer Biology", details actionable protocols for using MLN8237 in apoptosis and proliferation assays. While these articles primarily focus on the anti-proliferative and pro-apoptotic effects of Aurora A inhibition in cancer models, Li et al.'s work extends the paradigm by elucidating how Aurora A activity is also crucial for maintaining the epigenetic state in non-cancerous, trained immune cells.

Thus, the reference study not only complements the existing literature by providing a mechanistic bridge between metabolic regulation, immune memory, and tumor biology but also expands the investigative toolkit for researchers interested in the consequences of Aurora A inhibition beyond classical cell cycle control.

Limitations and Transferability

While the study offers compelling evidence that AurA activity is indispensable for trained immunity via regulation of SAM-dependent histone methylation, several limitations should be noted. First, although the mouse macrophage and tumor models are highly informative, the transferability of these findings to human systems and diverse tumor microenvironments remains to be fully established. Second, the pharmacological inhibitors used, while selective, may have off-target effects at higher concentrations; genetic validation, though included, is not a complete substitute for clinical context. Finally, the focus on β-glucan as a trained immunity inducer may not capture the full spectrum of stimuli relevant to clinical or translational settings.

Despite these caveats, the mechanistic insights into the mTOR–FOXO3–GNMT axis provide a strong foundation for future studies investigating how metabolic-epigenetic coupling regulates immune cell function in cancer and beyond.

Research Support Resources

Researchers aiming to model the effects of Aurora A kinase inhibition on trained immunity, apoptosis induction in tumor cells, or tumor growth inhibition in animal models can leverage selective tools such as MLN8237 (Alisertib) (SKU A4110). This compound functions as a potent and selective ATP-competitive Aurora A kinase inhibitor, well-suited for dissecting the molecular underpinnings of oncogenesis and tumor progression in vitro and in vivo. For detailed protocol guidance and troubleshooting, consult protocol-driven literature such as "MLN8237 (Alisertib): Protocol-Driven Workflows in Cancer Biology". When using MLN8237 from APExBIO, ensure solutions are freshly prepared and stored under recommended conditions to maintain compound stability and experimental reproducibility.